Product Details
Additional Information
| Product Name | Lynparza 150 mg Tab 120/Ea |
| Application | PARP Inhibitor for Cancer Treatment |
| Generic Drug Name | Olaparib |
| Mechanism of Action | Inhibits PARP enzymes, preventing DNA repair in cancer cells |
| Strength | 150 mg |
| Type | Oral |
| Volume | 120 tablets per bottle |
| Recommended Dosage | 300 mg (two 150 mg tablets) twice daily |
| Administration Instructions | Swallow whole, do not crush, chew, or split; can be taken with or without food |
| Half-life | ~12 hours |
| Common Adverse Effects | Nausea, anemia, fatigue, vomiting, diarrhea, decreased appetite |
| Serious Risks | Myelodysplastic syndrome, acute myeloid leukemia, pneumonitis, severe bone marrow suppression |
| Storage Conditions | Store at 20°C to 25°C (68°F to 77°F), protect from moisture and heat |
| Monitoring Requirements | Complete blood count (CBC), renal function, liver enzymes |
| Indications | BRCA-mutated ovarian, breast, pancreatic, and prostate cancers |
Description
Lynparza (Olaparib) 150 mg Tablets, 120/Ea is a poly (ADP-ribose) polymerase (PARP) inhibitor used in the treatment of certain cancers associated with BRCA mutations and homologous recombination repair (HRR) deficiencies. It is indicated for patients with advanced ovarian, breast, pancreatic, and prostate cancers who meet specific genetic and clinical criteria. By inhibiting PARP enzymes, it prevents DNA repair in cancer cells, leading to cell death and reduced tumor progression.
Lynparza is administered orally in a recommended dose of 300 mg (two 150 mg tablets) twice daily, totaling 600 mg per day. The tablets should be swallowed whole and not chewed, crushed, or split. Dosing adjustments may be required for patients with renal impairment or those experiencing severe adverse effects. It can be taken with or without food, and consistency in administration timing is recommended for optimal therapeutic effect.
Common adverse effects include nausea, fatigue, anemia, vomiting, diarrhea, and decreased appetite. Serious risks include myelodysplastic syndrome, acute myeloid leukemia, pneumonitis, and severe bone marrow suppression. Regular monitoring of complete blood counts (CBC), renal function, and liver enzymes is necessary during treatment to assess for toxicity.
Frequently Asked Questions (FAQs)
The cost of LYNPARZA 150MG TAB 120/EA is $available for registerd members only
LYNPARZA 150MG TAB 120/EA is manufactured by ASTRAZENECA.
You can purchase LYNPARZA 150MG TAB 120/EA on our website at https://supplies.pipelinemedical.com/product/detail/lynparza-150mg-tab-120-ea-422340